Article (Scientific journals)
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
Zatloukal, Petr; Gervais, Radj; Vansteenkiste, Johan et al.
2008In Journal of Thoracic Oncology, 3 (8), p. 894-901
Peer Reviewed verified by ORBi
 

Files


Full Text
Randomized Multicenter Phase II Study of Larotaxel _XRP9881_ in.pdf
Author postprint (118.69 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy/pathology; Cisplatin/administration & dosage; Deoxycytidine/administration & dosage/analogs & derivatives; Female; Humans; Lung Neoplasms/drug therapy/pathology; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids/administration & dosage
Abstract :
[en] INTRODUCTION: This randomized phase II study investigated the efficacy and safety of a new taxane, larotaxel (XRP9881), in combination with either cisplatin or gemcitabine in the first-line treatment of patients with nonirradiable stage IIIB or stage IV non-small cell lung cancer to select the combination having the most promising antitumor activity. METHODS: Patients received either larotaxel (50 mg/m) as a 1-hour infusion, followed by a 1-hour infusion of cisplatin (75 mg/m), every 3 weeks (arm A), or gemcitabine (800 mg/m) as a 30 minute infusion, on days 1 and 8, and larotaxel (60 mg/m) as a 1-hour infusion, on day 8 (following gemcitabine), every 3 weeks (arm B). The primary end point was the objective response rate (per-protocol population). RESULTS: Thirty-two patients were randomized to arm A and 30 to arm B. The response rate was higher in arm A compared with arm B in both the per-protocol (26.7% versus 18.2%) and intention-to-treat (28.1% versus 13.3%) populations. In the intention-to-treat population, median progression-free survival for arm A versus arm B was 4.7 versus 3.3 months and median overall survival was 8.6 versus 7.3 months, respectively. Fifty percent of patients in arm A and 66.7% in arm B experienced at least one National Cancer Institute common toxicity criteria grade 3/4 adverse event and grade 3/4 neutropenia was observed in 46.9% and 41.4% of patients, respectively. CONCLUSIONS: Both larotaxel combinations were effective and manageable, however all measured efficacy parameters (response rate, progression free survival, and survival) seemed to favor the combination with cisplatin.
Disciplines :
Cardiovascular & respiratory systems
Oncology
Author, co-author :
Zatloukal, Petr
Gervais, Radj
Vansteenkiste, Johan
Bosquee, Léon ;  Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Sessa, Christiana
Brain, Etienne
Dansin, Eric
Urban, Thierry
Dohollou, Nadine
Besenval, Michele
Quoix, Elisabeth
Language :
English
Title :
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
Publication date :
August 2008
Journal title :
Journal of Thoracic Oncology
ISSN :
1556-0864
eISSN :
1556-1380
Publisher :
Lippincott Williams & Wilkins, Philadelphia, United States - Pennsylvania
Volume :
3
Issue :
8
Pages :
894-901
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 14 April 2009

Statistics


Number of views
135 (5 by ULiège)
Number of downloads
381 (5 by ULiège)

Scopus citations®
 
27
Scopus citations®
without self-citations
27
OpenCitations
 
18

Bibliography


Similar publications



Contact ORBi